Cargando…

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine

Detalles Bibliográficos
Autores principales:	Zarra, Julio, Schmidt, Luisa
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991801/ http://dx.doi.org/10.1186/1744-859X-9-S1-S118

Ejemplares similares

Mild cognitive disorder and depression: treatment with combination of galantamine and escitalopram
por: Zarra, Julio, et al.
Publicado: (2010)

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano, Osamu, et al.
Publicado: (2013)

Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
por: Koola, Maju Mathew, et al.
Publicado: (2018)

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease
por: Reggiani, Angelo M., et al.
Publicado: (2016)

Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine
por: Koola, Maju Mathew
Publicado: (2016)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity
por: Lopes, João P, et al.
Publicado: (2013)

Galantamine improves cognition, behavioral symptoms and functioning: a 6-month non-interventional study
por: Doskas, Triantafyllos, et al.
Publicado: (2010)

PT596. The comparison with galantamine and donepezil on Alzheimer’s Disease patients and its relationship with cerebral blood flow
por: Wake, Rei, et al.
Publicado: (2016)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
por: Hager, Klaus, et al.
Publicado: (2016)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

PT592. Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-analysis
por: Matsunaga, Shinji, et al.
Publicado: (2016)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

The effect of memantine on cerebral cortex tumor necrosis factor alpha exression in a rat model of acute hyperammonemia
por: Tsartsalis, Stergios, et al.
Publicado: (2010)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis
por: Guo, Jiaxun, et al.
Publicado: (2020)

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
por: Atri, Alireza, et al.
Publicado: (2013)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
por: Marotta, Giambattista, et al.
Publicado: (2020)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias
por: Muayqil, Taim, et al.
Publicado: (2012)

Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy
por: Nanaki, Stavroula G., et al.
Publicado: (2020)

Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy
por: Georgieva, Dilyana, et al.
Publicado: (2023)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

Memantine-induced Myoclonus in a Patient with Alzheimer Disease
por: Murgai, Aditya A., et al.
Publicado: (2015)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

Multidimensional evaluation in clinical diagnosis of Alzheimer’s disease: genetic risk in Alzheimer’s disease and neurodegenerative dementias
por: Bruni, A C
Publicado: (2010)

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine
por: Schmidt, R, et al.
Publicado: (2008)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization
por: Sánchez-López, Elena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9gkaj0290e145l8qbak5jd7kbd